SANA Stock Up 49% after 6-Day Win Streak

SANA: Sana Biotechnology logo
SANA
Sana Biotechnology

Sana Biotechnology (SANA) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 49% return. The company has gained about $450 Mil in value over the last 6 days, with its current market capitalization at about $924 Mil. The stock remains 149.1% above its value at the end of 2024. This compares with year-to-date returns of 6.8% for the S&P 500.

Comparing SANA Stock Returns With The S&P 500

The following table summarizes the return for SANA stock vs. the S&P 500 index over different periods, including the current streak:

Return Period SANA S&P 500
1D 0.2% 0.3%
6D (Current Streak) 48.7% 1.2%
1M (21D) 43.0% 4.7%
3M (63D) 165.4% 24.1%
YTD 2025 149.1% 6.8%
2024 -60.0% 23.3%
2023 3.3% 24.2%
2022 -74.5% -19.4%

Gains and Losses Streaks: S&P 500 Constituents

There are currently 125 S&P constituents with 3 days or more of consecutive gains and 33 constituents with 3 days or more of consecutive losses.

Consecutive Days # of Gainers # of Losers
3D 100 19
4D 7 5
5D 3 6
6D 5 3
7D or more 10 0
Total >=3 D 125 33

 

Relevant Articles
  1. Get Paid 8.6% to Buy GOOGL at a 30% Discount – Here’s How
  2. What Could Spark the Next Big Move In Netflix Stock
  3. Why Amazon.com Stock May Drop Soon
  4. Cash Rich, Low Price – Gartner Stock to Break Out?
  5. Does Johnson & Johnson Stock Have More Upside?
  6. Has American Water Works Stock Quietly Become a Value Opportunity?

Key Financials for Sana Biotechnology (SANA)

Last 2 Fiscal Years:

Metric FY2023 FY2024
Revenues
Operating Income $-293.1 Mil $-272.7 Mil
Net Income $-283.3 Mil $-266.8 Mil

Last 2 Fiscal Quarters:

Metric 2024 FQ4 2025 FQ1
Revenues $- $-
Operating Income $-50.9 Mil $-50.6 Mil
Net Income $-49.1 Mil $-49.4 Mil

While SANA stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.